TY - JOUR
T1 - Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage
AU - Park, Jonghyuck
AU - Zheng, Lingxing
AU - Marquis, Andrew
AU - Walls, Michael
AU - Duerstock, Brad
AU - Pond, Amber
AU - Vega-Alvarez, Sasha
AU - Wang, He
AU - Ouyang, Zheng
AU - Shi, Riyi
PY - 2014/4
Y1 - 2014/4
N2 - Acrolein, an α,β-unsaturated aldehyde and a reactive product of lipid peroxidation, has been suggested as a key factor in neural post-traumatic secondary injury in spinal cord injury (SCI), mainly based on in vitro and ex vivo evidence. Here, we demonstrate an increase of acrolein up to 300%; the elevation lasted at least 2 weeks in a rat SCI model. More importantly, hydralazine, a known acrolein scavenger can provide neuroprotection when applied systemically. Besides effectively reducing acrolein, hydralazine treatment also resulted in significant amelioration of tissue damage, motor deficits, and neuropathic pain. This effect was further supported by demonstrating the ability of hydralazine to reach spinal cord tissue at a therapeutic level following intraperitoneal application. This suggests that hydralazine is an effective neuroprotective agent not only in vitro, but in a live animal model of SCI as well. Finally, the role of acrolein in SCI was further validated by the fact that acrolein injection into the spinal cord caused significant SCI-like tissue damage and motor deficits. Taken together, available evidence strongly suggests a critical causal role of acrolein in the pathogenesis of spinal cord trauma. Since acrolein has been linked to a variety of illness and conditions, we believe that acrolein-scavenging measures have the potential to be expanded significantly ensuring a broad impact on human health.
AB - Acrolein, an α,β-unsaturated aldehyde and a reactive product of lipid peroxidation, has been suggested as a key factor in neural post-traumatic secondary injury in spinal cord injury (SCI), mainly based on in vitro and ex vivo evidence. Here, we demonstrate an increase of acrolein up to 300%; the elevation lasted at least 2 weeks in a rat SCI model. More importantly, hydralazine, a known acrolein scavenger can provide neuroprotection when applied systemically. Besides effectively reducing acrolein, hydralazine treatment also resulted in significant amelioration of tissue damage, motor deficits, and neuropathic pain. This effect was further supported by demonstrating the ability of hydralazine to reach spinal cord tissue at a therapeutic level following intraperitoneal application. This suggests that hydralazine is an effective neuroprotective agent not only in vitro, but in a live animal model of SCI as well. Finally, the role of acrolein in SCI was further validated by the fact that acrolein injection into the spinal cord caused significant SCI-like tissue damage and motor deficits. Taken together, available evidence strongly suggests a critical causal role of acrolein in the pathogenesis of spinal cord trauma. Since acrolein has been linked to a variety of illness and conditions, we believe that acrolein-scavenging measures have the potential to be expanded significantly ensuring a broad impact on human health.
KW - acrolein scavenger
KW - aldehyde
KW - lipid peroxidation
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=84897985731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897985731&partnerID=8YFLogxK
U2 - 10.1111/jnc.12628
DO - 10.1111/jnc.12628
M3 - Article
C2 - 24286176
AN - SCOPUS:84897985731
SN - 0022-3042
VL - 129
SP - 339
EP - 349
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
IS - 2
ER -